MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$23.68
0.07 (0.30%)
▲
5d:
-1.62%
30d:
-18.43%
90d:
-36.53%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
MLYS is down 8.6% this week, but smart money is accumulating calls. Top strike: $30 2026-05-15 with 5,575 OI. Call ratio: 100% View Scanner →
Strength: 9.2/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $23.68, which is considered oversold relative to its 30-day fair value range of $24.56 to $28.91.
Technical Outlook: Technically, MLYS is in a strong downtrend. Immediate support is located at $22.42, while resistance sits at $26.98.
Market Sentiment: MLYS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $49.38 (+108.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MLYS is in a strong downtrend. Immediate support is located at $22.42, while resistance sits at $26.98.
Market Sentiment: MLYS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $49.38 (+108.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$24.56 -
$28.91
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 108.5% below Wall St target ($49.38)
Fair Price Analysis
30-Day Fair Range
$24.56 -
$28.91
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$22.42
Resistance Level
$26.98
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.94
Wall Street Target
$49.38
(+108.5%)
Share & Embed Analysis
Last updated: March 30, 2026 8:55 AM ET
Data refreshes hourly during market hours. Next update: 9:55 AM
Data refreshes hourly during market hours. Next update: 9:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
14058 shares
2026-03-13
David Malcom Rodman
SELL
6348 shares
2026-03-12
David Malcom Rodman
SELL
2171 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
